Proactive Investors - Run By Investors For Investors

Collagen Solutions raises around £215,000 from sale of small stake in private marine biotechnology firm, Jellagen

Jamal Rushdy, Collagen Solutions’ CEO said "our decision to divest our shares does not preclude future potential opportunities to collaborate with Jellagen"
Collagen
He added: “We are pleased with our return on this investment, which we can use to further support our own growth opportunities"

Collagen Solutions PLC (LON:COS) has raised around £215,000 from the sale of its stake in Jellagen Ltd. the private marine biotechnology company focused on developing collagen biomaterials from jellyfish in a private transaction.

The AIM-listed developer and manufacturer of biomaterials and regenerative medicines said it had held a minority equity position in Jellagen since 2014 and also collaborated on technology development.

READ: Collagen Solutions signs new ChondroMimetic licence and distribution deal in Indonesia

The move to sell the stake follows the most recent investment round in Jellagen in which the Collagen did not participate, the company added.

Jamal Rushdy, Collagen Solutions’ CEO, commented: "We remain interested in Jellagen's progress as it continues to develop its jellyfish collagen cell culture products for the research markets, and our decision to divest our shares does not preclude future potential opportunities to collaborate with Jellagen.

“We are pleased with our return on this investment, which we can use to further support our own growth opportunities."

View full COS profile View Profile

Collagen Solutions PLC Timeline

Related Articles

antibodies
May 02 2019
Avacta is using Affimers to develop its own cancer therapy, but it also licenses the technology to other companies, including major pharma group ModernaTX and LG Chem Life Sciences
Alliance
April 05 2019
Chief executive Peter Butterfield said the company has started 2019 well-positioned for growth after a strong performance in 2018.
blood
Fri
Belgium-based company’s Nu.Q test screens for colorectal and prostate cancers, and may have the potential to detect ovarian disease endometriosis

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use